Experienced in Mesothelioma

Dr. Mark A. Klein

Hematology Oncology
1 Veterans Dr, 111e Minneapolis Veterans Affairs Medical Center, 
Minneapolis, MN 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Mesothelioma
1 Veterans Dr, 111e Minneapolis Veterans Affairs Medical Center, 
Minneapolis, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Klein is a Hematologist Oncology provider in Minneapolis, Minnesota. Dr. Klein is rated as an Experienced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Pulmonary Embolism, Mesothelioma, Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC).

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Mesothelioma.

Specialties
Hematology Oncology
Licenses
Internal Medicine in MN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

1 Veterans Dr, 111e Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug
Study Drug: INC280
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
View 8 Less Clinical Trials

45 Total Publications

Treatment duration of immune checkpoint inhibitors and overall survival in U.S. veterans with Cancer.
Treatment duration of immune checkpoint inhibitors and overall survival in U.S. veterans with Cancer.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: July 11, 2025
Similar Doctors
Distinguished in Mesothelioma
Dr. Manish R. Patel
Hematology Oncology | Hematology | Oncology
Distinguished in Mesothelioma
Dr. Manish R. Patel
Hematology Oncology | Hematology | Oncology

Fairview Express Care

909 Fulton St Se, 
Minneapolis, MN 
 (4.9 miles away)
612-625-4800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manish Patel is a Hematologist Oncology specialist and a Hematologist in Minneapolis, Minnesota. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Lung Cancer, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Prostatectomy, and Nephrectomy. Dr. Patel is currently accepting new patients.

Advanced in Mesothelioma
Dr. John E. Seng
Hematology Oncology | Hematology | Oncology
Advanced in Mesothelioma
Dr. John E. Seng
Hematology Oncology | Hematology | Oncology

Minnesota Oncology Hematology PA

910 E 26th St, Suite 100 200, 
Minneapolis, MN 
 (4.6 miles away)
612-884-6300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Seng is a Hematologist Oncology specialist and a Hematologist in Minneapolis, Minnesota. Dr. Seng is rated as an Advanced provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Pancreatic Cancer, Familial Colorectal Cancer, Neuroendocrine Tumor, Bone Marrow Aspiration, and Gastrostomy. Dr. Seng is currently accepting new patients.

Advanced in Mesothelioma
Dr. Jesus Vera-Aguilera
Oncology | Hematology Oncology | Hematology
Advanced in Mesothelioma
Dr. Jesus Vera-Aguilera
Oncology | Hematology Oncology | Hematology

Minnesota Oncology Hematology PA

910 E 26th St, Suite 100 200, 
Minneapolis, MN 
 (4.6 miles away)
612-884-6300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jesus Vera-Aguilera is an Oncologist and a Hematologist Oncology provider in Minneapolis, Minnesota. Dr. Vera-Aguilera is rated as a Distinguished provider by MediFind in the treatment of Mesothelioma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Pancreatic Cancer, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vera-Aguilera is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Klein's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile